• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session

    3/31/23 12:47:51 PM ET
    $ADN
    $AEHR
    $ANGO
    $ANPC
    Industrial Machinery/Components
    Miscellaneous
    Electrical Products
    Industrials
    Get the next $ADN alert in real time by email

    Gainers

    • Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter.
    • Inpixon (NASDAQ:INPX) jumped 37.9% to $0.5101. Inpixon reported a 21% growth in revenue to $19.4 million for the 2022 fiscal year.
    • Toro Corp. (NASDAQ:TORO) surged 31.6% to $3.12.
    • Guardforce AI Co., Limited (NASDAQ:GFAI) gained 27% to $6.00.
    • IonQ, Inc. (NYSE:IONQ) rose 25.8% to $6.39 after clocking upbeat fourth-quarter results.
    • FOXO Technologies Inc. (NASDAQ:FOXO) gained 24.4% to $0.4612 following full year 2022 results.
    • Metropolitan Bank Holding Corp. (NYSE:MCB) gained 23% to $31.18 after the company issued updated financial information.
    • Palisade Bio, Inc. (NASDAQ:PALI) gained 22% to $3.23. Maxim Group upgraded the stock from Hold to Buy and announced a $50 price target.
    • Ault Alliance, Inc. (NASDAQ:AULT) surged 20% to $0.1126 after the company announced a share buyback of up to 333,333,333 shares of common stock at $0.15 per sare through an exchange offer for a new class of preferred stock.
    • Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) gained 19.2% to $2.98. BrainStorm Cell Therapeutics recently posted a 2022 net loss per share of $0.66.
    • GT Biopharma, Inc. (NASDAQ:GTBP) gained 19% to $0.55. GT Biopharma posted a FY22 loss of $0.66 per share.
    • ASP Isotopes Inc. (NASDAQ:ASPI) surged 18% to $1.05.
    • Rigetti Computing, Inc. (NASDAQ:RGTI) surged 17.8% to $0.7070. Rigetti Computing recently posted a Q1 loss of $0.19 per share.
    • D-Wave Quantum Inc. (NYSE:QBTS) climbed 15.5% to $0.60. D-Wave Quantum announced earnings report date change for Q4 and FY22 results to the week of April 10, 2023.
    • Cabaletta Bio, Inc. (NASDAQ:CABA) gained 14.7% to $8.15. Cabaletta Bio received FDA clearance of IND application for CABA-201 for treatment of systemic lupus erythematosus.
    • Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) jumped 14% to $2.4195.
    • BlackBerry Limited (NYSE:BB) gained 13.8% to $4.5550 after the company reported better-than-expected Q4 adjusted EPS results.
    • Inozyme Pharma, Inc. (NASDAQ:INZY) surged 13.8% to $5.34. Inozyme Pharma Director Robert Hopfner acquired a total of 344,592 shares at an average price of $4.54.
    • AngioDynamics, Inc. (NASDAQ:ANGO) jumped 11.4% to $10.14. AngioDynamics recently reported worse-than-expected Q3 revenue and reduced its 2023 revenue guidance.
    • Marqeta, Inc. (NASDAQ:MQ) rose 11% to $4.6250.
    • Digital Ally, Inc. (NASDAQ:DGLY) gained 9.2% to $4.16.
    • TORM plc (NASDAQ:TRMD) surged 8.3% to $30.90 after the company reported termination of secondary public offering of its Class A common shares by a selling shareholder.
    • Digital World Acquisition Corp. (NASDAQ:DWAC) gained 6.8% to $13.95 following the indictment of Donald Trump. Digital World is the business combination partner of Trump Media & Technology Group.
    • Rumble Inc. (NASDAQ:RUM) shares climbed 6% to $9.89 after the company reported better-than-expected Q4 results and a 142% year-over-year increase in global MAUs.

    Losers

    • Gorilla Technology Group Inc. (NASDAQ:GRRR) dipped 66% to $4.0150.
    • G Medical Innovations Holdings Ltd (NASDAQ:GMVD) fell 43% to $0.9354. G Medical Innovations Holdings announced pricing of $9.6 million public offering of 12 million shares of common stock at a price of $0.80 per share.
    • Virgin Orbit Holdings, Inc. (NASDAQ:VORB) fell 41.4% to $0.1994 on reports the company is ceasing operations for the foreseeable future and cutting nearly 90% of its workforce.
    • Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSE) shares fell 40% to $1.9090 after the company reported Q4 results and announced pricing of $10.8 million underwritten public offering of common stock.
    • Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) dropped 39.7% to $2.02. Checkpoint Therapeutics announced $6.1 million registered direct offering priced at-the-market under Nasdaq rules.
    • Pyxis Oncology, Inc. (NASDAQ:PYXS) fell 28.8% to $4.27.
    • Bioventus Inc. (NASDAQ:BVS) dropped 28% to $0.8721 following weaker-than-expected quarterly results.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) dipped 27.7% to $0.3038.
    • Bit Brother Limited (NASDAQ:BTB) fell 24% to $0.8584.
    • Professional Diversity Network, Inc. (NASDAQ:IPDN) dropped 24% to $3.22.
    • Ensysce Biosciences, Inc. (NASDAQ:ENSC) declined 23.6% to $5.19. Ensysce Biosciences posted a Q4 loss of $1.52 per share.
    • AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) dropped 22.7% to $4.24.
    • GAN Limited (NASDAQ:GAN) fell 22.4% to $1.3199 following a wider-than-expected quarterly loss.
    • CuriosityStream Inc. (NASDAQ:CURI) fell 22% to $1.2488 after the company reported downbeat quarterly results.
    • Apollomics Inc. (NASDAQ:APLM) dropped 21.8% to $23.00.
    • Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) fell 21.8% to $0.25.
    • AST SpaceMobile, Inc. (NASDAQ:ASTS) shares fell 21.2% to $5.04 after the company posted a wider Q4 loss.
    • Shapeways Holdings, Inc. (NYSE:SHPW) fell 20.6% to $0.3255 after the company reported weaker-than-expected results for its fourth quarter.
    • Annovis Bio, Inc. (NYSE:ANVS) dipped 20.4% to $16.00. Annovis Bio received interim analysis for sample size re-estimation for its Phase 3 clinical trial for treatment of early Parkinson's disease.
    • FaZe Holdings Inc. (NASDAQ:FAZE) fell 20.3% to $0.47. FaZe Holdings posted Q4 sales of $21.40 million.
    • ContraFect Corporation (NASDAQ:CFRX) dropped 18.7% to $1.78. ContraFect posted a Q4 loss of $16.14 per share.
    • Cano Health, Inc. (NYSE:CANO) fell 17.9% to $0.9272. Cano Health said it was disappointed that three directors chose to resign.
    • Charah Solutions, Inc. (NYSE:CHRA) dropped 17.8% to $2.16.
    • Nogin, Inc. (NASDAQ:NOGN) fell 16.2% to $2.90.
    • Siyata Mobile Inc. (NASDAQ:SYTA) dropped 15.6% to $0.1595.
    • Disc Medicine Opco Inc (NASDAQ:IRON) fell 15% to $18.69 after the company reported full year 2022 financial results.
    • Advent Technologies Holdings, Inc. (NASDAQ:ADN) fell 14.6% to $0.9994. Advent Technologies reported fourth-quarter FY22 revenue of $1.96 million, down 22% year-over-year.
    • Zura Bio Limited (NASDAQ:ZURA) dropped 14.4% to $13.55.
    • SHF Holdings, Inc. (NASDAQ:SHFS) shares fell 13.4% to $0.5189. SHF Hldgs posted a Q4 loss of $1.94 per share.
    • Aehr Test Systems (NASDAQ:AEHR) dropped 12.5% to $32.56 following Q3 results.
    • Nikola Corporation (NASDAQ:NKLA) fell 12.5% to $1.22 after the company announced pricing for a $100 million common stock offering.
    • E-Home Household Service Holdings Limited (NASDAQ:EJH) fell 12.4% to $0.1050 after dropping 9% on Thursday.
    • IGM Biosciences, Inc. (NASDAQ:IGMS) fell 12% to $14.98 after the company reported Q4 financial results.
    • TROOPS, Inc. (NASDAQ:TROO) dropped 7.7% to $3.23.

    Now Read This: Top 5 Industrials Stocks That Could Lead To Your Biggest Gains In March

    Get the next $ADN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADN
    $AEHR
    $ANGO
    $ANPC

    CompanyDatePrice TargetRatingAnalyst
    Aehr Test Systems
    $AEHR
    3/2/2026Mkt Perform → Outperform
    William Blair
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Marqeta Inc.
    $MQ
    2/17/2026$6.00Overweight
    Analyst
    D-Wave Quantum Inc.
    $QBTS
    2/12/2026Buy
    TD Cowen
    Rigetti Computing Inc.
    $RGTI
    2/12/2026Buy → Hold
    TD Cowen
    Bioventus Inc.
    $BVS
    2/9/2026$13.00Outperform
    Barrington Research
    Zura Bio Limited
    $ZURA
    2/9/2026$15.00Outperform
    Wedbush
    Rigetti Computing Inc.
    $RGTI
    1/22/2026$35.00Neutral → Buy
    B. Riley Securities
    More analyst ratings

    $ADN
    $AEHR
    $ANGO
    $ANPC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC

    Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:

    3/21/24 10:20:07 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUZYRA issued to PARATEK PHARMS INC

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-10) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209817, Application Classification: Efficacy

    5/31/21 5:18:25 AM ET
    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUZYRA issued to PARATEK PHARMS INC

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209816, Application Classification: Efficacy

    5/31/21 5:18:25 AM ET
    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $AEHR
    $ANGO
    $ANPC
    SEC Filings

    View All

    SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs

    6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    3/18/26 5:11:41 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Guardforce AI Co. Limited

    6-K - Guardforce AI Co., Ltd. (0001804469) (Filer)

    3/18/26 4:46:46 PM ET
    $GFAI
    Diversified Commercial Services
    Consumer Discretionary

    SEC Form S-8 filed by Gorilla Technology Group Inc.

    S-8 - Gorilla Technology Group Inc. (0001903145) (Filer)

    3/18/26 4:10:27 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    $ADN
    $AEHR
    $ANGO
    $ANPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Wisniewski Scott

    4 - AST SpaceMobile, Inc. (0001780312) (Issuer)

    3/18/26 8:25:26 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    SEC Form 3 filed by new insider Chen Hong-Jung

    3 - Apollomics Inc. (0001944885) (Issuer)

    3/18/26 6:52:25 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Chu Yi-An

    3 - Apollomics Inc. (0001944885) (Issuer)

    3/18/26 6:46:11 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $AEHR
    $ANGO
    $ANPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026

    AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2026 before the market open on Thursday, April 2, 2026. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the "Investors" section of the AngioD

    3/19/26 8:00:00 AM ET
    $ANGO
    Medical/Dental Instruments
    Health Care

    NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

    WASHINGTON, D.C., March 19, 2026 (GLOBE NEWSWIRE) -- NeuroRPM, a digital health company focused on Parkinson's disease monitoring, today announced that its FDA-cleared wearable platform will be used for digital biomarker monitoring in Annovis Bio's ANVS-25002 open-label Parkinson's disease clinical trial. NeuroRPM's platform uses the Apple Watch to passively collect and analyze movement data during daily activities, providing continuous measurement of key Parkinson's motor symptoms. The ANVS-25002 study is expected to enroll approximately 500 participants with Parkinson's disease across multiple clinical sites. Eligible participants may choose to take part in the NeuroRPM digital monitori

    3/19/26 7:30:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

    MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a partnership with NeuroRPM, a digital health technology company, to implement a new FDA-cleared artificial intelligence (AI) platform that collects movement data for symptom and disease management in its ongoing Parkinson's study. Annovis' recently launched open-label study in PD patients (ANVS-25002) is currently enrolling participants across the 25 sites in the United

    3/19/26 7:30:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $AEHR
    $ANGO
    $ANPC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aehr Test Systems upgraded by William Blair

    William Blair upgraded Aehr Test Systems from Mkt Perform to Outperform

    3/2/26 8:27:16 AM ET
    $AEHR
    Electrical Products
    Industrials

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Analyst resumed coverage on Marqeta with a new price target

    Analyst resumed coverage of Marqeta with a rating of Overweight and set a new price target of $6.00

    2/17/26 7:51:08 AM ET
    $MQ
    Computer Software: Prepackaged Software
    Technology

    $ADN
    $AEHR
    $ANGO
    $ANPC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Financial Officer Dougherty Daniel F bought $79,950 worth of shares (1,000 units at $79.95), increasing direct ownership by 3% to 32,197 units (SEC Form 4)

    4 - Metropolitan Bank Holding Corp. (0001476034) (Issuer)

    3/11/26 5:05:05 PM ET
    $MCB
    Major Banks
    Finance

    Large owner Ai Biotechnology Llc bought $12,500,000 worth of Class A Ordinary Shares (2,000,000 units at $6.25) (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    3/2/26 5:55:03 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Linville Judson C bought $100,383 worth of shares (25,570 units at $3.93) (SEC Form 4)

    4 - Marqeta, Inc. (0001522540) (Issuer)

    3/2/26 5:04:55 PM ET
    $MQ
    Computer Software: Prepackaged Software
    Technology

    $ADN
    $AEHR
    $ANGO
    $ANPC
    Leadership Updates

    Live Leadership Updates

    View All

    Quantum Leap Energy Appoints Nate Salpeter, Ph.D., a Key Opinion Leader in Fluid Dynamics and Energy Technology, as its Chief Technology Officer

    DALLAS, March 05, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI") today announced that Quantum Leap Energy LLC ("QLE" or the "Company"), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, has appointed Nate Salpeter, Ph.D. as its Chief Technology Officer. Dr. Salpeter is a recognized key opinion leader in the field of physics-constrained energy technology optimization, with more than 15 years of experience building computational frameworks, laser-based experimental methods, and first-of-kind engineering programs across nuclear energy and advanced thermal sys

    3/5/26 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    WorkWhile Names Simon Khalaf CEO as Company Enters Next Phase of Growth and Expands Into Worker Financial Services

    Co-Founder Jarah Euston transitions to President and COO; Platform surpasses 1.2 million workers SAN FRANCISCO, Feb. 25, 2026 /PRNewswire/ -- WorkWhile today announced a leadership transition as the company moves into its next phase of growth. Tech veteran and longtime board member Simon Khalaf has been named Chief Executive Officer. Co-Founder Jarah Euston will transition to President and Chief Operating Officer, where she will focus on scaling operations and accelerating expansion. The transition comes at a moment of strength for the company. WorkWhile now serves more than 1.2

    2/25/26 1:24:00 PM ET
    $MQ
    Computer Software: Prepackaged Software
    Technology

    Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date. "Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a

    2/23/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADN
    $AEHR
    $ANGO
    $ANPC
    Financials

    Live finance-specific insights

    View All

    AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026

    AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2026 before the market open on Thursday, April 2, 2026. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the "Investors" section of the AngioD

    3/19/26 8:00:00 AM ET
    $ANGO
    Medical/Dental Instruments
    Health Care

    TORM plc capital increase in connection with exercise of Restricted Share Units as part of TORM's incentive program

    HELLERUP, Denmark, March 16, 2026 /PRNewswire/ -- TORM plc (NASDAQ:TRMD) (NASDAQ:TRMD) has increased its share capital by 106,468 A-shares (corresponding to a nominal value of USD 1,064.68) as a result of the exercise of a corresponding number of Restricted Share Units ("RSUs"). A total of 34,880 new shares are subscribed for in cash at DKK 131.80 per A-share, and 71,588 new shares are subscribed for in cash at DKK 148.70. Transfer restrictions may apply in certain jurisdictions outside Denmark, including applicable US securities laws. The capital increase is carried out without any pre-emption rights for existing shareholders or others.The new shares (i) are ordinary shares without any spec

    3/16/26 4:21:00 AM ET
    $TRMD
    Marine Transportation
    Consumer Discretionary

    Rumble Reports Fourth Quarter and Full Year 2025 Results

    ~ Surpasses $100 Million in Annual Revenue, First Time in the Company's History ~ ~ MAUs of 52 Million in Q4, Representing 11% Quarterly Sequential Growth ~ ~ Recently Launched Rumble Shorts Tops 1 Million Daily Unique Video Views ~ ~ On Track to Complete Transformative Acquisition of AI Infrastructure Company, Northern Data, in the Second Quarter of 2026 ~ ~ Northern Data's GPU Utilization is Expected to Approximate 85% by End of Q1 20261 ~ LONGBOAT KEY, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Rumble Inc. (NASDAQ:RUM), the Freedom-First technology platform, today announced financial results for the fiscal quarter and full year ended December 31, 2025. Q4 2025 Key Highlights and Key

    3/5/26 4:05:00 PM ET
    $RUM
    Computer Software: Programming Data Processing
    Technology

    $ADN
    $AEHR
    $ANGO
    $ANPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Inozyme Pharma Inc.

    SC 13G - Inozyme Pharma, Inc. (0001693011) (Subject)

    12/9/24 4:14:49 PM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gorilla Technology Group Inc.

    SC 13G/A - Gorilla Technology Group Inc. (0001903145) (Subject)

    12/6/24 9:25:12 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care